rabeprazole / Generic mfg. - LARVOL DELTA

The Efficacy of Potassium-Competitive Acid Blocker Compared With Double Dose of Proton Pump Inhibitor in Patients With Refractory Gastro-Esophageal Reflux Disease: A Case-Control Study. (PubMed, Korean J Helicobacter Up Gastrointest Res) - "Double split doses of rabeprazole (20 mg) or tegoprazan (50 mg) were prescribed for 2 weeks, and the symptoms were subsequently evaluated. In patients with refractory GERD symptoms, PCAB therapy had effects corresponding to those of a double split dose of PPIs. PCAB therapy was therefore deemed superior to PPIs, especially in patients with abnormal AETs."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases. (PubMed, Medicine (Baltimore)) - "In the use of PPIs, we should pay attention to the occurrence of related adverse reactions, especially the damage to the infection-related adverse effects, monitor the relevant indicators, and take timely intervention measures to ensure the safety of medication."

Adverse events • Journal • Gastrointestinal Disorder • Infectious Disease • Pneumonia • Respiratory Diseases

Bioequivalence of a single dose of two palbociclib formulations in healthy Chinese subjects under fasting conditions: a two-period crossover study with rabeprazole pre-treatment. (PubMed, Front Pharmacol) - P1 | "Both formulations were safe and well tolerated. http://www.chinadrugtrials.org.cn, identifier CTR20232617; https://www.chictr.org.cn, identifier ChiCTR2400084355."

Clinical • Journal

CTN-03208-1: Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=112 | Completed | Sponsor: Lomond Therapeutics Holdings, Inc. | Active, not recruiting ➔ Completed

First-in-human • Trial completion • Acute Myelogenous Leukemia

Proton pump inhibitors and the risk of urolithiasis: A Mendelian randomization study. (PubMed, Medicine (Baltimore)) - "The genome-wide association studies (GWAS) of Omeprazole, Esomeprazole, Lansoprazole, and Rabeprazole medication can be obtained from GWAS catalog. In conclusion, our results suggest a causal relationship of PPIs to UL. For patients requiring antiacid therapy, esomeprazole may be a better option than Rabeprazole, especially in patients with high-risk factors for urolithiasis."

Journal • Renal Calculi • Urolithiasis

Bismuth-Based quintuple therapy: a step beyond quadruple regimens in H. Pylori treatment and the impact of patient compliance. (PubMed, BMC Gastroenterol) - "In this study, we demonstrated that bismuth-based quintuple therapy can be used as an alternative to bismuth-based quadruple therapies and other high-risk treatments. However, we also highlighted the critical importance of treatment adherence."

Compliance • Journal • Infectious Disease

Efficacy of 10 days high-dose and double-dose rabeprazole-based concomitant therapy for Helicobacter pylori eradication among Lebanese population: a pilot randomized controlled trial. (PubMed, BMC Gastroenterol) - "The use of high-dose PPI with 10 days of concomitant therapy (Group C) demonstrated the highest eradication rate among the study groups. This promising finding suggests a potential benefit of the high-dose PPI regimen with 10-day concomitant therapy but must be interpreted with caution; it warrants further investigation in a larger and adequately powered randomized controlled trial to confirm its efficacy and generalizability, given the pilot nature of this study."

Journal • Allergy • Celiac Disease • Extranodal Marginal Zone Lymphoma • Gastric Cancer • Gastroenterology • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Oncology

Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. (PubMed, J Pharmacol Sci) - "Basic research has revealed that omeprazole, a proton pump inhibitor (PPI), exerts preventive effects against OIPN...Notably, esomeprazole, lansoprazole, and rabeprazole, classified as PPIs, prevented oxaliplatin-induced cultured F11 neuronal cell damage, and repeated PPI administration prevented mechanical allodynia in rats. However, vonoprazan, a potassium ion-competitive acid blocker, did not exert such effects. Overall, our results highlight the class effects of PPIs against OIPN."

Journal • Pain

Innovative approaches in HELICOBACTER pylori therapy: Clinical trials and advancements in Gastro-Retentive drug delivery systems. (PubMed, Arab J Gastroenterol) - "The conventional treatment involves a triple therapy regimen combining Rabeprazole, Amoxicillin, and Clarithromycin with the effectiveness of 10-day versus 14-day courses. Further, it also includes conventional treatment, its drawbacks and alternative treatment approaches available. Additionally, it also discussed about various clinical trials that have been reported for the treatment of H. PYLORI."

Journal • Review • Anorexia • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism among Patients with Gastroesophageal Reflux Disease. (PubMed, Clin Gastroenterol Hepatol) - "A large proportion of patients with GERD who underwent CYP2C19 genotyping were rapid metabolizers of CYP2C19 and responded well to changing/adjusting PPIs accordingly."

Journal • Barrett Esophagus • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • CYP2C19

A Randomized Controlled Non-Inferiority Trial of a 10-Day Vonoprazan–Amoxicillin Dual Therapy for First-Line Helicobacter pylori Eradication in Community Populations (ChiCTR) - P4 | N=400 | Recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University; Wuxi Ninth People's Hospital

Head-to-Head • New P4 trial • Infectious Disease

Beyond the Usual Battle: Refractory Duodenal Ulcer From Overlapping Eosinophilic Enteritis and Esophagitis in a Young Soldier Requiring Combination Biologic Therapy (ACG 2025) - "She was started on rabeprazole and a six-food elimination diet without success...To our knowledge, this is the first report of combination vedolizumab and dupilumab for overlapping EGID involving the esophagus and duodenum...Chronologic timeline of diagnostics and therapeutics detailing endoscopy, imaging, therapies, and laboratory testing during evaluation of patient. Therapies are denoted as color specific bars under the corresponding dates of therapy and detailed further in the figure's legend."

Crohn's disease • Eosinophilia • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Peptic Ulcer • Respiratory Diseases • Tuberculosis

Trends in Proton Pump Inhibitor Utilization and Cost in the United States: A Six-Year Analysis of MEPS Data (2017–2022) (ACG 2025) - "Records were filtered for all PPI medications (dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole) using generic and brand names. Between 2017 and 2022, a total of 1,737,845 PPI prescriptions were recorded. Prescription volume peaked in 2018 (319,109) and declined to 232,418 in 2022 (−27.2%). Average total cost per prescription decreased from $86.75 in 2017 to $41.51 in 2022 (−52.2%)."

Effectiveness of the RAC Regimen for Helicobacter pylori Eradication in Peptic Ulcer Disease: A Meta-Analysis of Randomized Controlled Trials (ACG 2025) - "While triple therapy combining a proton pump inhibitor (PPI), amoxicillin, and clarithromycin has been widely used, treatment success is impacted by clarithromycin resistance and pharmacogenetic differences in PPI metabolism. Rabeprazole, a newer PPI with minimal CYP2C19 interaction, may offer improved efficacy in triple therapy regimens... Nineteen randomized controlled trials including 6,321 patients were analyzed. The pooled eradication rate of the RAC regimen was 0.85 (95% CI: 0.82–0.89, p < 0.001) via a random-effects model. Substantial heterogeneity was present (I² = 90.1%, Q = 168.69, p < 0.001), likely due to regional clarithromycin resistance, 7- vs."

Retrospective data • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • CYP2C19

Systematic Review: Comparison Between Proton Pump Inhibitors and Vonoprazan in Management of Gastric Ulcers, Helicobacter Gastritis, Gastroesophageal Reflux Disease and Post-Procedure Bleeding (ACG 2025) - "For GERD, VPZ is statistically superior to Rabeprazole but not with Esomeprazole, lansoprazole, and omeprazole. Results showed no statistically significant difference in the ulcer healing rate at week 2, 4, 6, and 8. The most effective regimen for treating peptic ulcer disease appears to be lansoprazole 30 mg at both 2 and 8 weeks. At the 4-week mark, pantoprazole 40 mg outperformed vonoprazan 20 mg in terms of efficacy."

Review • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Infectious Disease • Inflammation • Peptic Ulcer

Sexual Dysfunctions Associated with Proton Pump Inhibitors: Insights from VigiBase, the World Health Organization Pharmacovigilance Database. (PubMed, Drug Saf) - "Findings of this study suggest the presence of safety signals of PPI-induced sexual dysfunctions, such as erectile dysfunction, genital discomfort and oestrogen deficiency. However, further observational studies are required to validate and further characterise these potential safety signals."

Adverse events • Journal • Endocrine Disorders • Erectile Dysfunction • Sexual Disorders

Vitamin B12 Deficiency Associated with Metformin and Proton Pump Inhibitors and Their Combinations: Results from a Disproportionality and Interaction Analysis. (PubMed, Diseases) - "These findings suggest that patients receiving metformin and PPIs together, particularly the elderly, may face a higher risk of serious vitamin B12 deficiency-related complications. Clinicians should consider closer monitoring of vitamin B12 levels and supplementation when needed in patients on combination therapy."

Journal • Gastrointestinal Disorder

Comparative evaluation of pregnancy-related adverse events associated with proton pump inhibitors using the FDA adverse event reporting system database. (PubMed, Int J Clin Pharm) - "This study detected potential disproportionality signals, suggesting an association between PPIs use during pregnancy and reported AEs. Certain signals appeared to be drug-specific rather than class-specific, such as omeprazole for postpartum hemorrhage and preeclampsia, lansoprazole for pregnancy on contraceptives, and pantoprazole for morning sickness. However, these findings should be regarded as exploratory and hypothesis generating, warranting cautious interpretation and confirmation through rigorously designed epidemiological and clinical studies."

Adverse events • Journal • Gynecology • Hematological Disorders • Postpartum Hemorrhage

Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study (ACR Convergence 2025) - "We compared GERD, or dyspepsia patients on PPIs (Esomeprazole, Dexlansoprazole, Lansoprazole, Pantoprazole, Omeprazole, Rabeprazole, Vonoprazan), with GERD, or dyspepsia patients not on PPIs. Patients with GERD, or dyspepsia, using PPI therapy have higher risks for autoimmune disease development, compared to those patients, not on PPI therapy. Further research is warranted to elucidate the pathways through which alterations in the gut microbiota contribute to the pathogenesis of autoimmune diseases."

Retrospective data • Alzheimer's Disease • Ankylosing Spondylitis • Cardiovascular • CNS Disorders • Dementia • Dermatomyositis • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Genetic Disorders • Genito-urinary Cancer • Giant Cell Arteritis • Immunology • Infectious Disease • Inflammatory Arthritis • Ischemic stroke • Musculoskeletal Diseases • Myocardial Infarction • Myositis • Osteoporosis • Psoriatic Arthritis • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Scleroderma • Seronegative Spondyloarthropathies • Sjogren's Syndrome • Systemic Sclerosis • Vasculitis

Optimizing Proton-pump Inhibitor Therapy in Patients with Comorbidities Receiving Polypharmacy Treatment: Insights from Clinical Practice in India. (PubMed, J Assoc Physicians India) - "Rabeprazole appears to be the preferred PPI in managing GERD among patients on polypharmacy, primarily due to its favorable safety profile and minimal DDI, and may be advantageous in clinical practice."

Journal • Cardiovascular • Gastroenterology • Gastroesophageal Reflux Disease

MANAGEMENT OF SEVERE EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (EGERD) WITH HIGH-DOSE PROTON PUMP INHIBITORS: INTERIM RESULTS FROM A REAL-WORLD OBSERVATIONAL STUDY (POWER 3.0) (UEGW 2025) - "The interim results showed that rabeprazole led to significantly higher complete-resolution rates of diurnal and nocturnal regurgitation at 4±1 weeks of treatment than omeprazole/esomeprazole in adults with severe eGERD. In elderly patients, rabeprazole showed significant resolution over pantoprazole."

Clinical • Late-breaking abstract • Observational data • Real-world • Real-world evidence • Gastroenterology • Gastroesophageal Reflux Disease

ESOPHAGEAL FUNCTION TESTING IDENTIFIES ASYMPTOMATIC BARRETT'S ESOPHAGUS PATIENTS WITH PATHOLOGICAL ACID EXPOSURE AT RISK FOR NEOPLASIA: A MULTICENTER STUDY (UEGW 2025) - "Maximal PPI therapy included esomeprazole 40 mg, pantoprazole 40 mg, rabeprazole 20 mg, or lansoprazole 30 mg, all administered twice daily. Nearly one-third of asymptomatic BE patients exhibit pathological reflux on pH-monitoring despite PPI treatment, predominantly among those on standard-dose and with manometric hiatal hernia. Nonetheless, adequate acid control is achieved in over one-third of patients on standard PPI therapy. Pathological reflux is associated with a 10-fold increased risk of neoplasia."

Clinical • Barrett Esophagus • Gastrointestinal Disorder

Helicobacter Pylori Infection and Gastric Disease in Bhutan: First Community-Wide, Population-Based Study (clinicaltrials.gov) - P=N/A | N=1043 | Completed | Sponsor: Zero Helicobacter IGAN Network

New trial • Gastric Cancer • Infectious Disease • Oncology • Solid Tumor

Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH. (PubMed, Mol Pharm) - "Geometric mean Cmax and AUC0-tz were similar after treatment with zongertinib SDD with and without rabeprazole. Zongertinib SDD formulation showed good bioavailability irrespective of pH, supporting further clinical development."

Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH A TWO-FOLD INCREASED RISK OF LIVER TRANSPLANT COMPLICATIONS: A PROPENSITY-MATCHED ANALYSIS OF 48,192 RECIPIENTS (AASLD 2025) - "LT recipients were identified and stratified into two cohorts: those receiving PPIs (omeprazole, pantoprazole, esomeprazole, rabeprazole, or lansoprazole) post-transplant and those without PPI exposure. PPI use was common in the post-transplant setting and was associated with a two-fold increased risk of overall complications, a four-fold increased risk of transplant-related infections, and a six-fold risk of re-transplantation. Several mechanisms may explain these findings, including PPI-induced reduction in mycophenolate absorption leading to subtherapeutic immunosuppression, alterations in gut microbiota promoting bacterial translocation, impaired neutrophil function, and potential drug interactions with calcineurin inhibitors. These findings suggest the need for judicious PPI prescribing in LT recipients and warrant prospective studies to establish causality and optimal acid suppression strategies."

Hepatology • Infectious Disease • Liver Cirrhosis • Transplantation